Saturday 17 October 2026
Export DARE’s income statement to Excel — free account
Dare Bioscience, Inc.
DARE Healthcare Biotechnology
Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024. In the quarter to June 2026, revenue grew 984.4%, EPS grew 55.6% and free cash flow fell 30.2%, each against the same quarter a year earlier.
0.72
0.02
−2.70%
Follow DARE
Dare Bioscience, Inc. (DARE) P/E ratio
Dare Bioscience, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.1× (March 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.1×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. | n/m |
| GTBP GT Biopharma, Inc. compare | n/m |
| TVRD Tvardi Therapeutics, Inc. compare | n/m |
| RVLP RVL Pharmaceuticals PLC compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| CNSY Cerenome, Inc. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| CLVSQ Clovis Oncology, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)